A Phase 1/2 Feasibility, Safety, and Activity Study of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) in Subjects with Previously Treated Advanced Solid Tumors
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Bellicum Pharmaceuticals, Inc.
Start Date
July 14, 2022
End Date
June 5, 2027
Administered By
Duke Cancer Institute
Awarded By
Bellicum Pharmaceuticals, Inc.
Start Date
July 14, 2022
End Date
June 5, 2027